AIDS TREATMENT NEWS No. 067 - October 21, 1988
John S. James
The rules essentially codify what was already done with AZT. They ask drug companies to work more closely with the FDA to design an expanded phase II (efficacy study), after which drugs could be released without going through a phase III (larger efficacy study). But there are no commitments to use the new procedures in any particular situations; and some have questioned whether the FDA has enough money or staff to handle accelerated approvals.
These rules were adopted after months of bitter infighting behind the scenes. Powerful FDA officials who never wanted this reform may try to sabotage it.
The previous "treatment IND" (now called "treatment proto- col") remains as before. In theory those rules permit the early release of treatment for life-threatening or severely debilitating illness; in practice they have almost never been used since they were announced over a year ago.
The current new rules do not change the real intentions and operations of the agency concerning early release of drugs before full commercial approval. The FDA still adamantly refuses to allow early release through the treatment protocol (treatment IND) unless it believes that the data supports approval for full commercial marketing and only paperwork remains. The treatment protocol can be used only to get the drug to patients during the time of this considerable paperwork; it is only a steppingstone toward commercial release. The FDA sees no drug as eligible for commercial release (and therefore none eligible for a treatment protocol) at this time.
For reasons outlined in "Beyond an Unreasonable Doubt", below, we believe that this new FDA ruling will do nothing for AIDS in the foreseeable future, probably nothing for at least two years. Yet it may be an important long-range step toward improving U. S. drug regulation.
Martin Delaney, co-founder of Project Inform, called the rules "only a small step, not the whole solution to the problems we have been addressing for the last three years... Nevertheless, they stake out new philosophical ground for the agency, ack- nowledging for the first time that drugs must be evaluated flexibly, that the rules should be different when a life-threatening illness is involved, and that approval should be based on a risk-benefit analysis rather than rigid, standard rules."
For a copy of the new rule, which will appear in the Code of Federal Regulations, 21 CFR 312 as a new Subpart E, "Drugs Intended to Treat Life-Threatening and Severely-Debilitating Illnesses", send a self-addressed stamped envelope to AIDS Treatment News, P. O. Box 411256, San Francisco, CA 94141. Ask for the FDA rule.
881021
ATN06703
Copyright © 1988 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org
Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .